Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study. (October 2022)

• Record Type: Journal Article
• Authors: Svendsen, Karianne; Olsen, Thomas; Vinknes, Kathrine J.; Mundal, Liv J.; Holven, Kirsten B.; Bogsrud, Martin P.; Leren, Trond P.; Igland, Jannicke; Retterstøl, Kjetil
• Is Part Of: Atherosclerosis. Volume 358(2022)
• Page Start: 34
• Page End: 40
• Publication Date: 2022-10
• Subjects: FH -- Stroke -- Hypercholesterolemia -- Registry -- Statins -- Anti-thrombotic medication; Arteriosclerosis -- Periodicals; Electronic journals; 616.136
• DOI: 10.1016/j.atherosclerosis.2022.08.015
• Languages: English
• ISSNs: 0021-9150

Abstract

Abstract: Background and aims: Individuals with familial hypercholesterolemia (FH), causing severely elevated LDL-C, are expected to have a higher risk of ischemic stroke. The risk of hemorrhagic stroke and impact of statin use are, however, not known. We aimed to investigate the risk of incident total, ischemic and hemorrhagic stroke in individuals with FH compared to controls, and to explore the association between cumulative statin use and risk of total stroke in FH. Methods: This prospective cohort study consists of 4186 individuals with genetically verified FH and 82 180 age and sex matched controls followed from 2008 to 2018 for incident stroke. Daily defined doses (DDD) described cumulative statin exposure: 0–5000 DDD ("low"), 5000–10, 000 DDD ("intermediate"), and >10 000 DDD ("high"). Results were presented as hazard ratio (95% CI) derived from Cox proportional hazards models. Results: Individuals with FH did not have a higher risk of total stroke (1.16 (0.95–1.43) nor ischemic stroke (1.11 (0.88–1.38). Excess risk of hemorrhagic stroke was observed (1.63 (1.07, 2.48) but attenuated after adjusting for antithrombotic medication (1.25 (0.81, 1.93). Among individuals with FH, there was no association between statin use and total stroke for intermediate vs. low DDD [0.69 (0.32, 1.48)] or for high vs. low DDD [0.83 (0.41, 1.67)]. Conclusions: No significant excess risk of incident total and ischemic stroke in FH, and no difference in total stroke risk among the FH population with low, intermediate, and high statin exposure were observed. The observed relationship between FH and hemorrhagic stroke was no longer significant after adjusting for use of anti-thrombotic medication. Graphical abstract: Image 1 Highlights: Individuals with familial hypercholesterolemia (FH) do not have excess risk of total or ischemic stroke. Excess risk of hemorrhagic stroke in FH was observed. Use of anti-thrombotic medication attenuated the relationship between hemorrhagic stroke and FH. Similar risk of total stroke among FH individuals with high vs. low cumulative statin exposure.